# EDGAR Filing Document

**Accession Number:** 0000277751
**File Stem:** 0001741773-23-000822
**Filing Date:** 2023-3
**Character Count:** 72632
**Document Hash:** 6bf4cebb871ff74c4aa1b0190fde5fcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001741773-23-000822.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001741773-23-000822

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**PERIOD START**: 20230930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JANUS INVESTMENT FUND
- **CENTRAL INDEX KEY:** 0000277751
- **IRS NUMBER:** 840592523
- **STATE OF INCORPORATION:** MA

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-01879
- **FILM NUMBER:** 23691695

**BUSINESS ADDRESS:**
- **STREET 1:** 151 DETROIT STREET
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80206
- **BUSINESS PHONE:** 303-333-3863

**MAIL ADDRESS:**
- **STREET 1:** 151 DETROIT STREET
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80206

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JANUS FUND /MD/
- **DATE OF NAME CHANGE:** 19870701

## Series and Classes Contracts Data

### Janus Henderson Global Life Sciences Fund (Series ID: S000010494)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000028956 | Class T      | JAGLX           |
| C000077752 | Class A      | JFNAX           |
| C000077753 | Class C      | JFNCX           |
| C000077754 | Class I      | JFNIX           |
| C000077755 | Class S      | JFNSX           |
| C000083538 | Class D      | JNGLX           |
| C000198286 | Class N      | JFNNX           |

## Nport-Ex

### Janus Henderson Global Life Sciences Fund

#### Schedule of Investments (unaudited)

#### December 31, 2022

---

| | | |
|:---|:---|:---|
| *Shares or*<br>*Principal Amounts* | *Shares or*<br>*Principal Amounts* | *Value* |
| Common Stocks– 97.5% | Common Stocks– 97.5% |  |
| Biotechnology – 30.9% | Biotechnology – 30.9% |  |
| 4D Molecular Therapeutics Inc\* | 444198 | $9865638 |
| AbbVie Inc | 1141497 | 184477330 |
| Akero Therapeutics Inc\* | 1001770 | 54896996 |
| Alnylam Pharmaceuticals Inc\* | 172691 | 41040016 |
| Altimmune Inc\*<sup>,#</sup> | 1030773 | 16956216 |
| Amgen Inc | 192933 | 50671923 |
| Amicus Therapeutics Inc\* | 2548195 | 31113461 |
| Apellis Pharmaceuticals Inc\* | 830045 | 42921627 |
| Arcellx Inc\*<sup>,#</sup> | 429038 | 13291597 |
| Ardelyx, Inc.\* | 2941625 | 8383631 |
| Argenx SE (ADR)\* | 204129 | 77330189 |
| Ascendis Pharma A/S (ADR)\* | 456948 | 55807059 |
| Bicycle Therapeutics Ltd (ADR)\*<sup>,#</sup> | 528203 | 15634809 |
| BioAtla LLC\*<sup>,#</sup> | 486009 | 4009574 |
| BioCryst Pharmaceuticals Inc\* | 491126 | 5638126 |
| Biohaven Ltd\* | 1022578 | 14193383 |
| BioMarin Pharmaceutical Inc\* | 623591 | 64535433 |
| Biomea Fusion Inc\* | 729522 | 6149870 |
| C4 Therapeutics Inc\* | 335365 | 1978654 |
| CANbridge Pharmaceuticals Inc\* | 3901000 | 1224529 |
| Centessa Pharmacuticals PLC (ADR)\*<sup>,#</sup> | 691173 | 2142636 |
| Cerevel Therapeutics Holdings Inc\* | 463125 | 14606963 |
| Design Therapeutics Inc\*<sup>,#</sup> | 492234 | 5050321 |
| Gilead Sciences Inc | 372723 | 31998270 |
| Horizon Therapeutics PLC\* | 536977 | 61107983 |
| Insmed Inc\* | 916817 | 18318004 |
| IVERIC bio Inc\* | 1136126 | 24324458 |
| Janux Therapeutics Inc\* | 582596 | 7672789 |
| Legend Biotech Corp (ADR)\* | 520392 | 25977969 |
| Mirati Therapeutics Inc\* | 107105 | 4852928 |
| Neurocrine Biosciences Inc\* | 465421 | 55589884 |
| Olema Pharmaceuticals Inc\* | 745574 | 1826656 |
| Prothena Corp PLC\* | 425921 | 25661740 |
| PTC Therapeutics Inc\* | 569062 | 21721097 |
| Regeneron Pharmaceuticals Inc\* | 63386 | 45732365 |
| Rhythm Pharmaceuticals Inc\* | 578774 | 16853899 |
| Sage Therapeutics Inc\* | 246058 | 9384652 |
| Sarepta Therapeutics Inc\* | 950822 | 123207515 |
| Seres Therapeutics Inc\* | 3055514 | 17110878 |
| Travere Therapeutics Inc\* | 1508504 | 31723839 |
| United Therapeutics Corp\* | 159472 | 44347569 |
| Vaxcyte Inc\* | 1081918 | 51877968 |
| Vertex Pharmaceuticals Inc\* | 341726 | 98683634 |
| Zai Lab Ltd (ADR)\* | 659746 | 20254202 |
|  |  | 1460148280 |
| Health Care Equipment & Supplies – 14.3% | Health Care Equipment & Supplies – 14.3% |  |
| Abbott Laboratories | 1006808 | 110537450 |
| Align Technology Inc\* | 150379 | 31714931 |
| Boston Scientific Corp\* | 2324190 | 107540271 |
| Cooper Cos Inc | 113786 | 37625617 |
| Dentsply Sirona Inc | 436233 | 13889659 |
| DexCom Inc\* | 307960 | 34873390 |
| Edwards Lifesciences Corp\* | 512609 | 38245758 |
| Globus Medical Inc\*<sup>,#</sup> | 492818 | 36601593 |
| ICU Medical Inc\* | 77275 | 12169267 |
| Insulet Corp\* | 29389 | 8651828 |
| Intuitive Surgical Inc\* | 147101 | 39033250 |
| Medtronic PLC | 448902 | 34888663 |
| Penumbra Inc\* | 171746 | 38206615 |
| Silk Road Medical Inc\* | 226996 | 11996739 |
| STERIS PLC | 170535 | 31496109 |
| Stryker Corp | 193356 | 47273608 |
| Tandem Diabetes Care Inc\* | 214236 | 9629908 |
| Teleflex Inc | 121410 | 30307578 |
|  |  | 674682234 |
| Health Care Providers & Services – 13.9% | Health Care Providers & Services – 13.9% |  |
| AmerisourceBergen Corp | 356754 | 59117705 |
| Anthem Inc | 174058 | 89286532 |

---

------

---

| | | |
|:---|:---|:---|
| *Shares or*<br>*Principal Amounts* | *Shares or*<br>*Principal Amounts* | *Value* |
| Common Stocks– (continued) | Common Stocks– (continued) |  |
| Health Care Providers & Services– (continued) | Health Care Providers & Services– (continued) |  |
| Centene Corp\* | 983771 | $80679060 |
| Humana Inc | 180953 | 92682317 |
| Privia Health Group Inc\* | 403412 | 9161487 |
| Quest Diagnostics Inc | 90306 | 14127471 |
| UnitedHealth Group Inc | 585776 | 310566720 |
|  |  | 655621292 |
| Life Sciences Tools & Services – 6.7% | Life Sciences Tools & Services – 6.7% |  |
| Danaher Corp | 363803 | 96560592 |
| ICON PLC\* | 82452 | 16016301 |
| Illumina Inc\* | 221199 | 44726438 |
| IQVIA Holdings Inc\* | 157906 | 32353360 |
| NeoGenomics Inc\* | 1668087 | 15413124 |
| SomaLogic Inc\* | 1019345 | 2558556 |
| Thermo Fisher Scientific Inc | 199869 | 110065860 |
|  |  | 317694231 |
| Pharmaceuticals – 31.7% | Pharmaceuticals – 31.7% |  |
| Astellas Pharma Inc | 2950200 | 44764574 |
| AstraZeneca PLC | 1531969 | 207867500 |
| Bayer AG | 538151 | 27782115 |
| Bristol-Myers Squibb Co | 1387567 | 99835446 |
| Catalent Inc\* | 308457 | 13883650 |
| Collegium Pharmaceutical Inc\* | 616212 | 14296118 |
| DICE Therapeutics Inc\*<sup>,#</sup> | 372367 | 11617850 |
| Edgewise Therapeutics Inc\*<sup>,#</sup> | 391509 | 3500090 |
| Elanco Animal Health Inc\* | 1422724 | 17385687 |
| Eli Lilly & Co | 385587 | 141063148 |
| Harmony Biosciences Holdings Inc\* | 369021 | 20333057 |
| Jazz Pharmaceuticals PLC\* | 415258 | 66154752 |
| Johnson & Johnson | 287224 | 50738120 |
| Merck & Co Inc | 1276139 | 141587622 |
| Novartis AG (ADR) | 1405032 | 127464503 |
| Novo Nordisk A/S | 634265 | 85894288 |
| Organon & Co | 1827838 | 51051515 |
| Pfizer Inc | 1253293 | 64218733 |
| Roche Holding AG | 341911 | 107478640 |
| Royalty Pharma PLC - Class A | 952283 | 37634224 |
| Sanofi | 1269194 | 122790520 |
| Takeda Pharmaceutical Co Ltd | 781236 | 24404929 |
| Ventyx Biosciences Inc\*<sup>,#</sup> | 533449 | 17491793 |
|  |  | 1499238874 |
| Total Common Stocks (cost $3,055,002,987) | Total Common Stocks (cost $3,055,002,987) | 4607384911 |
| Private Placements– 1.8% | Private Placements– 1.8% |  |
| Biotechnology – 1.1% | Biotechnology – 1.1% |  |
| Arbor Biotechnologies Inc\*<sup>,¢,§</sup> | 156426 | 2591979 |
| Asher Biotherapeutics Inc\*<sup>,¢,§</sup> | 1214301 | 1951139 |
| Attralus Inc\*<sup>,¢,§</sup> | 669935 | 3483662 |
| Curevo Inc\*<sup>,¢,§</sup> | 2031087 | 5330344 |
| Disc Medicine Inc\*<sup>,§</sup> | 1084584 | 2127899 |
| Element Biosciences Inc\*<sup>,¢,§</sup> | 425023 | 6991628 |
| Flame Biosciences\*<sup>,¢,§</sup> | 919200 | 2837662 |
| HemoShear Therapeutics LLC\*<sup>,¢,§</sup> | 289280 | 2109430 |
| LEXEO Therapeutics Inc - Series A\*<sup>,¢,§</sup> | 3643715 | 6268975 |
| LEXEO Therapeutics Inc - Series B\*<sup>,¢,§</sup> | 883469 | 1520000 |
| Shoreline Biosciences Inc\*<sup>,¢,§</sup> | 747187 | 6017769 |
| Sonoma Biotherapeutics Inc\*<sup>,¢,§</sup> | 1924628 | 5705560 |
| Synthekine Inc\*<sup>,¢,§</sup> | 2192937 | 5661001 |
| TwinStrand Biosciences Inc\*<sup>,¢,§</sup> | 344314 | 749606 |
|  |  | 53346654 |
| Health Care Providers & Services – 0.4% | Health Care Providers & Services – 0.4% |  |
| Bigfoot Biomedical Inc - Series B\*<sup>,¢,§</sup> | 1035873 | 8440811 |
| Bigfoot Biomedical Inc - Series C-1\*<sup>,¢,§</sup> | 168418 | 1372354 |
| Freenome Holdings Inc\*<sup>,¢,§</sup> | 342803 | 4000511 |
| Freenome Inc\*<sup>,¢,§</sup> | 337474 | 3938322 |
|  |  | 17751998 |
| Health Care Technology – 0% | Health Care Technology – 0% |  |
| Magnolia Medical Technologies Inc - Series D\*<sup>,¢,§</sup> | 1821717 | 3092693 |
| Pharmaceuticals – 0.3% | Pharmaceuticals – 0.3% |  |
| Neurogene Inc\*<sup>,¢,§</sup> | 1336317 | 3260613 |
| Neurogene Inc - Series B\*<sup>,¢,§</sup> | 1486727 | 3627614 |
| VALENZABio - Series A\*<sup>,¢,§</sup> | 700559 | 6235276 |
|  |  | 13123503 |
| Total Private Placements (cost $95,149,445) | Total Private Placements (cost $95,149,445) | 87314848 |

---

------

---

| | | |
|:---|:---|:---|
| *Shares or*<br>*Principal Amounts* | *Shares or*<br>*Principal Amounts* | *Value* |
| Rights– 0% | Rights– 0% |  |
| Pharmaceuticals – 0% | Pharmaceuticals – 0% |  |
| Clementia Pharmaceuticals Inc CVR\*<sup>,¢</sup>((cost $1,180,320) | 874311 | $0 |
| Warrants– 0% | Warrants– 0% |  |
| Health Care Technology – 0% | Health Care Technology – 0% |  |
| Magnolia Medical Technologies Inc - Series D, expires 12/31/22\*<sup>,¢,§</sup>((cost $0) | 1 | 0 |
| Investment Companies– 0.4% | Investment Companies– 0.4% |  |
| Money Markets – 0.4% | Money Markets – 0.4% |  |
| Janus Henderson Cash Liquidity Fund LLC, 4.2633%<sup>ºº,£</sup>((cost $16,895,173) | 16893319 | 16896698 |
| Investments Purchased with Cash Collateral from Securities Lending– 0.4% | Investments Purchased with Cash Collateral from Securities Lending– 0.4% |  |
| Investment Companies – 0.3% | Investment Companies – 0.3% |  |
| Janus Henderson Cash Collateral Fund LLC, 4.1397%<sup>ºº,£</sup> | 16361734 | 16361734 |
| Time Deposits – 0.1% | Time Deposits – 0.1% |  |
| Royal Bank of Canada, 4.3100%, 1/3/23 | $4091257 | 4091257 |
| Total Investments Purchased with Cash Collateral from Securities Lending (cost $20,452,991) | Total Investments Purchased with Cash Collateral from Securities Lending (cost $20,452,991) | 20452991 |
| Total Investments (total cost $3,188,680,916) – 100.1% | Total Investments (total cost $3,188,680,916) – 100.1% | 4732049448 |
| Liabilities, net of Cash, Receivables and Other Assets – (0.1)% | Liabilities, net of Cash, Receivables and Other Assets – (0.1)% | (5800305) |
| Net Assets – 100% | Net Assets – 100% | $4726249143 |

---

---

| | | |
|:---|:---|:---|
| ***Summary of Investments by Country - (Long Positions) (unaudited)*** | ***Summary of Investments by Country - (Long Positions) (unaudited)*** | ***Summary of Investments by Country - (Long Positions) (unaudited)*** |
|  |  | *% of* |
|  |  | *Investment* |
| *Country* | *Value* | *Securities* |
| United States | $3797335290 | 80.2% |
| Switzerland | 234943143 | 5.0 |
| United Kingdom | 223502309 | 4.7 |
| Denmark | 141701347 | 3.0 |
| France | 122790520 | 2.6 |
| Belgium | 77330189 | 1.6 |
| Japan | 69169503 | 1.5 |
| Germany | 27782115 | 0.6 |
| China | 21478731 | 0.5 |
| Ireland | 16016301 | 0.3 |

---

---

| | | | |
|:---|:---|:---|:---|
| Total | $4732049448 | 100.0 | % |

---

------

#### Schedules of Affiliated Investments – (% of Net Assets)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Dividend*<br>*Income* | *Realized*<br>*Gain/(Loss)* | *Change in*<br>*Unrealized*<br>*Appreciation/* <br>*Depreciation* | *Value*<br>*at 12/31/22* |
| Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% |
| Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% |
| Janus Henderson Cash Liquidity Fund LLC, 4.2633%<sup>ºº</sup> | $253831 | $1561 | $1290 | $16896698 |
| Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% |
| Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% |
| Janus Henderson Cash Collateral Fund LLC, 4.1397%<sup>ºº</sup> | 102667<sup>∆</sup> | - | - | 16361734 |
| Total Affiliated Investments - 0.7% | $356498 | $1561 | $1290 | $33258432 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Value*<br> *at 9/30/22* | *Purchases* | *Sales Proceeds* | *Value*<br>*at 12/31/22* |
| Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% | Investment Companies - 0.4% |
| Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% | Money Markets - 0.4% |
| Janus Henderson Cash Liquidity Fund LLC, 4.2633%<sup>ºº</sup> | 5298938 | 289181865 | (277586956) | 16896698 |
| Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% | Investments Purchased with Cash Collateral from Securities Lending - 0.3% |
| Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% | Investment Companies - 0.3% |
| Janus Henderson Cash Collateral Fund LLC, 4.1397%<sup>ºº</sup> | 21402690 | 89720294 | (94761250) | 16361734 |

---

------

#### Notes to Schedule of Investments (unaudited)

---

| | |
|:---|:---|
| ADR | American Depositary Receipt |
| CVR | Contingent Value Right |
| LLC | Limited Liability Company |
| PLC | Public Limited Company |

---

<br> \* Non-income producing security.

<br> ºº Rate shown is the 7-day yield as of December 31, 2022.

<br> # Loaned security; a portion of the security is on loan at December 31, 2022.

---

| | |
|:---|:---|
| ¢ | Security is valued using significant unobservable inputs. The total value of Level 3 securities as of the period ended December 31, 2022 is $85,186,949, which represents 1.8% of net assets. |

---

£The Fund may invest in certain securities that are considered affiliated companies. As defined by the Investment Company Act of 1940, as amended, an affiliated company is one in which the Fund owns 5% or more of the outstanding voting securities, or a company which is under common ownership or control.<br>

∆ Net of income paid
to the securities lending agent and rebates paid to the borrowing counterparties.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| § | Schedule of Restricted Securities (as of December 31, 2022) | Schedule of Restricted Securities (as of December 31, 2022) | Schedule of Restricted Securities (as of December 31, 2022) | Schedule of Restricted Securities (as of December 31, 2022) | Schedule of Restricted Securities (as of December 31, 2022) | Schedule of Restricted Securities (as of December 31, 2022) |
|  |  |  |  |  | *Value as a* |  |
|  |  | *Acquisition* |  |  | *% of Net* |  |
|  |  | *Date* | *Cost* | *Value* | *Assets* |  |
| Arbor Biotechnologies Inc | Arbor Biotechnologies Inc | 10/29/21 | $2591979 | $2591979 | 0.1 | % |
| Asher Biotherapeutics Inc | Asher Biotherapeutics Inc | 8/23/21 | 2438924 | 1951139 | 0.0 |  |
| Attralus Inc | Attralus Inc | 8/31/21 | 5198696 | 3483662 | 0.1 |  |
| Bigfoot Biomedical Inc - Series B | Bigfoot Biomedical Inc - Series B | 11/21/17 | 9808940 | 8440811 | 0.2 |  |
| Bigfoot Biomedical Inc - Series C-1 | Bigfoot Biomedical Inc - Series C-1 | 12/27/19 | 1355580 | 1372354 | 0.0 |  |
| Curevo Inc | Curevo Inc | 11/10/22 | 5330344 | 5330344 | 0.1 |  |
| Disc Medicine Inc | Disc Medicine Inc | 8/23/21 | 2603002 | 2127899 | 0.0 |  |
| Element Biosciences Inc | Element Biosciences Inc | 6/21/21 | 8737070 | 6991628 | 0.2 |  |
| Flame Biosciences | Flame Biosciences | 9/28/20 | 6020760 | 2837662 | 0.1 |  |
| Freenome Holdings Inc | Freenome Holdings Inc | 11/22/21 | 2585523 | 4000511 | 0.1 |  |
| Freenome Inc | Freenome Inc | 8/14/20 | 2231817 | 3938322 | 0.1 |  |
| HemoShear Therapeutics LLC | HemoShear Therapeutics LLC | 2/5/21 | 3839496 | 2109430 | 0.1 |  |
| LEXEO Therapeutics Inc - Series A | LEXEO Therapeutics Inc - Series A | 11/20/20-7/30/21 | 3643715 | 6268975 | 0.1 |  |
| LEXEO Therapeutics Inc - Series B | LEXEO Therapeutics Inc - Series B | 8/10/21 | 1520000 | 1520000 | 0.0 |  |
| Magnolia Medical Technologies Inc - Series D, 12/31/22 | Magnolia Medical Technologies Inc - Series D, 12/31/22 | 1/10/22 | 0 | 0 | 0.0 |  |
| Magnolia Medical Technologies Inc - Series D | Magnolia Medical Technologies Inc - Series D | 1/10/22 | 3092693 | 3092693 | 0.0 |  |
| Neurogene Inc | Neurogene Inc | 12/15/20-9/22/21 | 3260613 | 3260613 | 0.1 |  |
| Neurogene Inc - Series B | Neurogene Inc - Series B | 3/4/22 | 3627614 | 3627614 | 0.1 |  |
| Shoreline Biosciences Inc | Shoreline Biosciences Inc | 10/28/21 | 7522230 | 6017769 | 0.1 |  |
| Sonoma Biotherapeutics Inc | Sonoma Biotherapeutics Inc | 7/23/21-12/14/22 | 4465171 | 5705560 | 0.1 |  |
| Synthekine Inc | Synthekine Inc | 6/3/21 | 6290001 | 5661001 | 0.1 |  |
| TwinStrand Biosciences Inc | TwinStrand Biosciences Inc | 4/30/21 | 2750001 | 749606 | 0.0 |  |
| VALENZABio - Series A | VALENZABio - Series A | 3/25/21 | 6235276 | 6235276 | 0.1 |  |
| Total | Total |  | $95149445 | $87314848 | 1.8 | % |
| The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. | The Fund has registration rights for certain restricted securities held as of December 31, 2022. The issuer incurs all registration costs. |

---

------

---

| | | | |
|:---|:---|:---|:---|
| The following is a summary of the inputs that were used to value the Fund's investments in securities and other financial instruments as of December 31, 2022. | The following is a summary of the inputs that were used to value the Fund's investments in securities and other financial instruments as of December 31, 2022. | The following is a summary of the inputs that were used to value the Fund's investments in securities and other financial instruments as of December 31, 2022. | The following is a summary of the inputs that were used to value the Fund's investments in securities and other financial instruments as of December 31, 2022. |
| **Valuation Inputs Summary** | **Valuation Inputs Summary** | **Valuation Inputs Summary** | **Valuation Inputs Summary** |
|  |  | ***Level 2 -*** | ***Level 3 -*** |
|  | ***Level 1 -*** | ***Other Significant*** | ***Significant*** |
|  | ***Quoted Prices*** | ***Observable Inputs*** | ***Unobservable Inputs*** |
| **Assets** |  |  |  |
| **Investments In Securities:** |  |  |  |
| *Common Stocks* |  |  |  |
| Pharmaceuticals | $878256308 | $620982566 | $- |
| All Other | 3108146037 | - | - |
| *Private Placements* | - | 2127899 | 85186949 |
| *Rights* | - | - | 0 |
| *Warrants* | - | - | 0 |
| *Investment Companies* | - | 16896698 | - |
| *Investments Purchased with Cash Collateral from Securities Lending* | - | 20452991 | - |
| **Total Assets** | $3986402345 | $660460154 | $85186949 |

---

------

#### Investment Valuation
Fund holdings are valued in accordance with policies and procedures established by the Adviser pursuant to Rule 2a-5 under the 1940 Act and approved by and subject to the oversight of the Trustees (the "Valuation Procedures"). Equity securities traded on a domestic securities exchange are generally valued at readily available market quotations, which are (i) the official close prices or (ii) last sale prices on the primary market or exchange in which the securities trade. If such price is lacking for the trading period immediately preceding the time of determination, such securities are generally valued at their current bid price. Equity securities that are traded on a foreign exchange are generally valued at the closing prices on such markets. In the event that there is no current trading volume on a particular security in such foreign exchange, the bid price from the primary exchange is generally used to value the security. Foreign securities and currencies are converted to U.S. dollars using the current spot USD dollar exchange rate in effect at the close of the New York Stock Exchange ("NYSE"). The Fund will determine the market value of individual securities held by it by using prices provided by one or more approved professional pricing services or, as needed, by obtaining market quotations from independent broker-dealers. Most debt securities are valued in accordance with the evaluated bid price supplied by the Adviser-approved pricing service that is intended to reflect market value. The evaluated bid price supplied by the pricing service is an evaluation that may consider factors such as security prices, yields, maturities and ratings. Certain short-term securities maturing within 60 days or less may be evaluated and valued on an amortized cost basis provided that the amortized cost determined approximates market value. Securities for which market quotations or evaluated prices are not readily available or deemed unreliable are valued at fair value determined in good faith by the Adviser pursuant to the Valuation Procedures. Circumstances in which fair valuation may be utilized include, but are not limited to: (i) a significant event that may affect the securities of a single issuer, such as a merger, bankruptcy, or significant issuer-specific development; (ii) an event that may affect an entire market, such as a natural disaster or significant governmental action; (iii) a nonsignificant event such as a market closing early or not opening, or a security trading halt; and (iv) pricing of a nonvalued security and a restricted or nonpublic security. Special valuation considerations may apply with respect to "odd-lot" fixed-income transactions which, due to their small size, may receive evaluated prices by pricing services which reflect a large block trade and not what actually could be obtained for the odd-lot position. The valuation policies provide for the use of systematic fair valuation models provided by independent pricing services to value foreign equity securities in order to adjust for stale pricing, which may occur between the close of certain foreign exchanges and the close of the NYSE. The value of the securities of other mutual funds held by a Fund, if any, will be calculated using the NAV of such mutual funds.

#### Valuation Inputs Summary
FASB ASC 820, Fair Value Measurements and Disclosures ("ASC 820"), defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements regarding fair value measurements. This standard emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability and establishes a hierarchy that prioritizes inputs to valuation techniques used to measure fair value. These inputs are summarized into three broad levels:

Level 1 – Unadjusted quoted prices in active markets the Fund has the ability to access for identical assets or liabilities.

Level 2 – Observable inputs other than unadjusted quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Assets or liabilities categorized as Level 2 in the hierarchy generally include: debt securities fair valued in accordance with the evaluated bid or ask prices supplied by a pricing service; securities traded on OTC markets and listed securities for which no sales are reported that are fair valued at the latest bid price (or yield equivalent thereof) obtained from one or more dealers transacting in a market for such securities or by a pricing service approved by the Fund's Trustees; certain short-term debt securities with maturities of 60 days or less that are fair valued at amortized cost; and equity securities of foreign issuers whose fair value is determined by using systematic fair valuation models provided by independent third parties in order to adjust for stale pricing which may occur between the close of certain foreign exchanges and the close of the NYSE. Other securities that may be categorized as Level 2 in the hierarchy include, but are not limited to, preferred stocks, bank loans, swaps, investments in unregistered investment companies, options, and forward contracts.

Level 3 – Unobservable inputs for the asset or liability to the extent that relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions that a market participant would use in valuing the asset or liability, and that would be based on the best information available. For restricted equity securities and private placements where observable inputs are limited, assumptions about market activity and risk are used in employing valuation techniques such as the market approach, the income approach, or the cost approach, as defined under the ASC 820. These are categorized as Level 3 in the hierarchy.

All other assets categorized as Level 3 in the hierarchy have been fair valued based on transaction price or transaction price adjusted for current market conditions using a comparable index or cost. The value of level 3 investments will increase should the future transaction price increase.

------

There have been no significant changes in valuation techniques used in valuing any such positions held by the Fund since the beginning of the fiscal year.

The inputs or methodology used for fair valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of inputs used as of December 31, 2022 to fair value the Fund's investments in securities and other financial instruments is included in the "Valuation Inputs Summary" in the Notes to Schedule of Investments.

The following describes the amounts of transfers into or out of Level 3 of the fair value hierarchy during the year.

Financial assets of $1,769,255 were transferred out of Level 3 to Level 2 since certain security's prices were determined using other significant observable inputs at the end of the current fiscal year and significant unobservable inputs at the end of the prior fiscal year.

------

For additional information on the Fund, please refer to the Fund's most recent semiannual or annual shareholder report.

125-25-70226 03-23<br>

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** JANUS INVESTMENT FUND

- **b. Investment Company Act file number:** 811-01879

- **c. CIK number of Registrant:** 0000277751

- **d. LEI of Registrant:** W6UYDZFUOFJ4HQQ32382

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 151 DETROIT STREET

  - **City:** DENVER

  - **State:** CO

  - **Foreign country:** US

  - **Zip / Postal Code:** 80206

  - **Telephone number:** 3033333863

**Item A.2. Information about the Series.**

- **a. Name of Series:** Janus Henderson Global Life Sciences Fund

- **b. EDGAR series identifier (if any):** S000010494

- **c. LEI of Series:** 5493001MPP2BKRJEGV73

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-09-30

- **b. Date as of which information is reported:** 2022-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $4744758393.00

**Total Liabilities:** $18525450.00

**Net Assets:** $4726232943.00

**Cash Not Reported:** $414782.00

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000077752 | -0.90%               | 6.00%                | 8.54%                |
| Class ID C000077753 | -0.95%               | 5.92%                | 8.48%                |
| Class ID C000083538 | -0.89%               | 6.02%                | 8.55%                |
| Class ID C000077754 | -0.87%               | 6.01%                | 8.56%                |
| Class ID C000198286 | -0.87%               | 6.03%                | 8.56%                |
| Class ID C000077755 | -0.93%               | 5.98%                | 8.51%                |
| Class ID C000028956 | -0.90%               | 6.01%                | 8.53%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $19697417.00             | $-61966880.00                              |
| Month 2  | $19835307.00             | $249811539.00                              |
| Month 3  | $-17718063.00            | $358291995.00                              |

**Designated Index Information**

- **Index Name:** MSCI THE WORLD INDEX / Health Care

- **Index Identifier:** MSCI.MC.MXWO0HC

### Schedule of Portfolio Investments

| Name                                 | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| N/A                                  | Royal Bank of Canada                     | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | CORP              | US        |   4091257 | PA      | $4091257.00   | 0.09%             | 2023-01-03      | Fixed         | 4.31%                 | No            |                  2 | On Loan: No      |
| Abbott Laboratories                  | Abbott Laboratories                      | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |   1006808 | NS      | $110537450.00 | 2.34%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                           | AbbVie Inc                               | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |   1141497 | NS      | $184477330.00 | 3.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Akero Therapeutics Inc               | Akero Therapeutics Inc                   | CUSIP: 00973Y108<br>LEI: 549300SI3KG74LBE2955 | Long             | EC               | CORP              | US        |   1011052 | NS      | $55405650.00  | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Align Technology Inc                 | Align Technology Inc                     | CUSIP: 016255101<br>LEI: 549300N5YSE0U3LCP840 | Long             | EC               | CORP              | US        |    150379 | NS      | $31714931.00  | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc          | Alnylam Pharmaceuticals Inc              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |    172691 | NS      | $41040016.00  | 0.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Altimmune Inc                        | Altimmune Inc                            | CUSIP: 02155H200<br>LEI: 549300EOYCQ8SW3NVE64 | Long             | EC               | CORP              | US        |   1030773 | NS      | $16956216.00  | 0.36%             |  |  |  | No            |                  1 | On Loan: —       |
| AmerisourceBergen Corp               | AmerisourceBergen Corp                   | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |    354052 | NS      | $58669957.00  | 1.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                            | Amgen Inc                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |    191860 | NS      | $50390110.00  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Amicus Therapeutics Inc              | Amicus Therapeutics Inc                  | CUSIP: 03152W109<br>LEI: 549300MRD1SMUTNBPQ53 | Long             | EC               | CORP              | US        |   2548195 | NS      | $31113461.00  | 0.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Elevance Health Inc                  | Anthem Inc                               | CUSIP: 036752103<br>LEI: 8MYN82XMYQH89CTMTH67 | Long             | EC               | CORP              | US        |    174058 | NS      | $89286532.00  | 1.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Apellis Pharmaceuticals Inc          | Apellis Pharmaceuticals Inc              | CUSIP: 03753U106<br>LEI: 254900HS0ZFRXXSB9D42 | Long             | EC               | CORP              | US        |    830045 | NS      | $42921627.00  | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                          | Arcellx Inc                              | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    429038 | NS      | $13291597.00  | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Ardelyx Inc                          | Ardelyx, Inc.                            | CUSIP: 039697107<br>LEI: 549300F542QR4SXHCY32 | Long             | EC               | CORP              | US        |   2941625 | NS      | $8383631.00   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| BioCryst Pharmaceuticals Inc         | BioCryst Pharmaceuticals Inc             | CUSIP: 09058V103<br>LEI: 549300Z0INP1Z5NP6J59 | Long             | EC               | CORP              | US        |    317975 | NS      | $3650353.00   | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| BioMarin Pharmaceutical Inc          | BioMarin Pharmaceutical Inc              | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |    623591 | NS      | $64535433.00  | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Biomea Fusion Inc                    | Biomea Fusion Inc                        | CUSIP: 09077A106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    729522 | NS      | $6149870.00   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| BioAtla Inc                          | BioAtla LLC                              | CUSIP: 09077B104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    486009 | NS      | $4009574.00   | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |
| AstraZeneca PLC                      | AstraZeneca PLC                          | CUSIP: G0593M107<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |   1531969 | NS      | $207867500.00 | 4.40%             |  |  |  | No            |                  2 | On Loan: No      |
| Boston Scientific Corp               | Boston Scientific Corp                   | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |   2324190 | NS      | $107540271.00 | 2.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co              | Bristol-Myers Squibb Co                  | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |   1387567 | NS      | $99835446.00  | 2.11%             |  |  |  | No            |                  1 | On Loan: No      |
| C4 Therapeutics Inc                  | C4 Therapeutics Inc                      | CUSIP: 12529R107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    335365 | NS      | $1978654.00   | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Catalent Inc                         | Catalent Inc                             | CUSIP: 148806102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    308457 | NS      | $13883650.00  | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Centene Corp                         | Centene Corp                             | CUSIP: 15135B101<br>LEI: 549300Z7JJ4TQSQGT333 | Long             | EC               | CORP              | US        |    983771 | NS      | $80679060.00  | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Cerevel Therapeutics Holdings        | Cerevel Therapeutics Holdings Inc COM    | CUSIP: 15678U128<br>LEI: 254900RJNIRS9COSQR41 | Long             | EC               | CORP              | US        |    463125 | NS      | $14606962.00  | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Collegium Pharmaceutical Inc         | Collegium Pharmaceutical Inc             | CUSIP: 19459J104<br>LEI: 54930049FXZMTLW8D496 | Long             | EC               | CORP              | US        |    616212 | NS      | $14296118.00  | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Cooper Cos Inc/The                   | Cooper Cos Inc                           | CUSIP: 216648402<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |    113786 | NS      | $37625617.00  | 0.80%             |  |  |  | No            |                  1 | On Loan: No      |
| DICE Therapeutics Inc                | DICE Therapeutics Inc                    | CUSIP: 23345J104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    372367 | NS      | $11617850.00  | 0.25%             |  |  |  | No            |                  1 | On Loan: —       |
| Danaher Corp                         | Danaher Corp                             | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    363803 | NS      | $96560592.00  | 2.04%             |  |  |  | No            |                  1 | On Loan: No      |
| DENTSPLY SIRONA Inc                  | DENTSPLY SIRONA Inc                      | CUSIP: 24906P109<br>LEI: 9NHEHR1SOZCYXDO8HO28 | Long             | EC               | CORP              | US        |    436233 | NS      | $13889659.00  | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Design Therapeutics Inc              | Design Therapeutics Inc                  | CUSIP: 25056L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    492234 | NS      | $5050321.00   | 0.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Dexcom Inc                           | DexCom Inc                               | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |    307960 | NS      | $34873390.00  | 0.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Edgewise Therapeutics Inc            | Edgewise Therapeutics Inc                | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    391509 | NS      | $3500090.00   | 0.07%             |  |  |  | No            |                  1 | On Loan: —       |
| Edwards Lifesciences Corp            | Edwards Lifesciences Corp                | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    512609 | NS      | $38245757.00  | 0.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Elanco Animal Health Inc             | Elanco Animal Health Inc                 | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |   1422724 | NS      | $17385687.00  | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Magnolia Medical Technologies Inc    | Magnolia Medical Technologies Inc        | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |         1 | NS      | $0.00         | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SomaLogic Inc                        | SomaLogic Inc                            | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |    722708 | NS      | $1.00         | 0.00%             |  |  |  | Yes           |                  2 | On Loan: No      |
| 4D Molecular Therapeutics Inc        | 4D Molecular Therapeutics Inc            | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    444198 | NS      | $9865638.00   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                  | Gilead Sciences Inc                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    372723 | NS      | $31998270.00  | 0.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Globus Medical Inc                   | Globus Medical Inc                       | CUSIP: 379577208<br>LEI: 5299003M2P4CIK0RF205 | Long             | EC               | CORP              | US        |    492818 | NS      | $36601593.00  | 0.77%             |  |  |  | No            |                  1 | On Loan: —       |
| Harmony Biosciences Holdings I       | Harmony Biosciences Holdings Inc         | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    352927 | NS      | $19446278.00  | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc                           | HUMANA INC                               | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |    180953 | NS      | $92682317.00  | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |
| ICU Medical Inc                      | ICU Medical Inc                          | CUSIP: 44930G107<br>LEI: 5493003NRW7LS2QZRH60 | Long             | EC               | CORP              | US        |     77275 | NS      | $12169267.00  | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                         | ILLUMINA INC                             | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |    221199 | NS      | $44726438.00  | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                           | Insmed Inc                               | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |    916817 | NS      | $18318004.00  | 0.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp                         | Insulet Corp                             | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |     29389 | NS      | $8651828.00   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical Inc               | Intuitive Surgical Inc                   | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |    147101 | NS      | $39033250.00  | 0.83%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                   | IQVIA Holdings Inc                       | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |    157906 | NS      | $32353360.00  | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| IVERIC bio Inc                       | IVERIC bio Inc                           | CUSIP: 46583P102<br>LEI: 549300GZXI59U71XPM70 | Long             | EC               | CORP              | US        |   1136126 | NS      | $24324458.00  | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Janux Therapeutics Inc               | Janux Therapeutics Inc                   | CUSIP: 47103J105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    582596 | NS      | $7672789.00   | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                    | Johnson & Johnson                        | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    287224 | NS      | $50738120.00  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Bayer AG                             | Bayer AG                                 | CUSIP: D0712D163<br>LEI: 549300J4U55H3WP1XT59 | Long             | EC               | CORP              | DE        |    538151 | NS      | $27782115.00  | 0.59%             |  |  |  | No            |                  2 | On Loan: No      |
| Eli Lilly & Co                       | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    386933 | NS      | $141555569.00 | 3.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi                               | Sanofi                                   | CUSIP: F5548N101<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |   1269194 | NS      | $122790520.00 | 2.60%             |  |  |  | No            |                  2 | On Loan: No      |
| Merck & Co Inc                       | Merck & Co Inc                           | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |   1276139 | NS      | $141587622.00 | 3.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Mirati Therapeutics Inc              | Mirati Therapeutics Inc                  | CUSIP: 60468T105<br>LEI: 529900GYRW59IDQV6N54 | Long             | EC               | CORP              | US        |    107105 | NS      | $4852928.00   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| NeoGenomics Inc                      | NeoGenomics Inc                          | CUSIP: 64049M209<br>LEI: 549300KN62PPGHBVXB46 | Long             | EC               | CORP              | US        |   1668087 | NS      | $15413124.00  | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc           | Neurocrine Biosciences Inc               | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |    465421 | NS      | $55589884.00  | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Olema Pharmaceuticals Inc            | Olema Pharmaceuticals Inc                | CUSIP: 68062P106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    745574 | NS      | $1826656.00   | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Organon & Co                         | Organon & Co COMMON STOCK                | CUSIP: 68622V106<br>LEI: 549300AMCKY57OK2CO56 | Long             | EC               | CORP              | US        |   1827838 | NS      | $51051515.00  | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Takeda Pharmaceutical Co Ltd         | Takeda Pharmaceutical Co Ltd             | CUSIP: J8129E108<br>LEI: 549300ZLMVP4X0OGR454 | Long             | EC               | CORP              | JP        |    781836 | NS      | $24423673.00  | 0.52%             |  |  |  | No            |                  2 | On Loan: No      |
| PTC Therapeutics Inc                 | PTC Therapeutics Inc                     | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |    569062 | NS      | $21721097.00  | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Astellas Pharma Inc                  | Astellas Pharma Inc                      | CUSIP: J03393105<br>LEI: 529900IB708DY2HBBB35 | Long             | EC               | CORP              | JP        |   2952500 | NS      | $44799473.00  | 0.95%             |  |  |  | No            |                  2 | On Loan: No      |
| Penumbra Inc                         | Penumbra Inc                             | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |    171746 | NS      | $38206615.00  | 0.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                     | Roche Holding AG                         | CUSIP: H69293217<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |    341911 | NS      | $107478640.00 | 2.27%             |  |  |  | No            |                  2 | On Loan: No      |
| Pfizer Inc                           | Pfizer Inc                               | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |   1253293 | NS      | $64218733.00  | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Privia Health Group Inc              | Privia Health Group Inc                  | CUSIP: 74276R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    403412 | NS      | $9161487.00   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Quest Diagnostics Inc                | Quest Diagnostics Inc                    | CUSIP: 74834L100<br>LEI: 8MCWUBXQ0WE04KMXBX50 | Long             | EC               | CORP              | US        |     90306 | NS      | $14127471.00  | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc        | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     63386 | NS      | $45732365.00  | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc           | Rhythm Pharmaceuticals Inc               | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |    578774 | NS      | $16853899.00  | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Sage Therapeutics Inc                | Sage Therapeutics Inc                    | CUSIP: 78667J108<br>LEI: 5493000JX4BJS9W6CN35 | Long             | EC               | CORP              | US        |    246058 | NS      | $9384652.00   | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Sarepta Therapeutics Inc             | Sarepta Therapeutics Inc                 | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |    950822 | NS      | $123207515.00 | 2.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Seres Therapeutics Inc               | Seres Therapeutics Inc                   | CUSIP: 81750R102<br>LEI: 549300GMXBE5NUWISF13 | Long             | EC               | CORP              | US        |   3055514 | NS      | $17110878.00  | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Silk Road Medical Inc                | Silk Road Medical Inc                    | CUSIP: 82710M100<br>LEI: 549300VL8KC0ZPDQHE14 | Long             | EC               | CORP              | US        |    226996 | NS      | $11996739.00  | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| SomaLogic Inc                        | SomaLogic Inc                            | CUSIP: 83444K105<br>LEI: 549300D3W3Q8CN30YO25 | Long             | EC               | CORP              | US        |   1019345 | NS      | $2558556.00   | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp                         | Stryker Corp                             | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |    193356 | NS      | $47273608.00  | 1.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Tandem Diabetes Care Inc             | Tandem Diabetes Care Inc                 | CUSIP: 875372203<br>LEI: 549300JEPFOD0K4D3I05 | Long             | EC               | CORP              | US        |    214236 | NS      | $9629908.00   | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Teleflex Inc                         | Teleflex Inc                             | CUSIP: 879369106<br>LEI: UUL85LWXB4NGSWWXIQ25 | Long             | EC               | CORP              | US        |    121410 | NS      | $30307578.00  | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc         | THERMO FISHER SCIENTIFIC INC             | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |    199869 | NS      | $110065860.00 | 2.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Travere Therapeutics Inc             | Travere Therapeutics Inc                 | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1508504 | NS      | $31723839.00  | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Janus Capital Group Inc              | Janus Henderson Cash Liquidity Fund      | CUSIP: N/A<br>LEI: 8T2ZO87FU1KVPZIG9I59       | Long             | EC               | PF                | US        |  16893319 | NS      | $16896698.00  | 0.36%             |  |  |  | No            |                  2 | On Loan: No      |
| Janus Henderson Cash Collateral Fund | Janus Henderson Cash Collateral Fund     | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | PF                | US        |  16361734 | NS      | $16361734.00  | 0.35%             |  |  |  | No            |                  2 | On Loan: No      |
| United Therapeutics Corp             | United Therapeutics Corp                 | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |    159472 | NS      | $44347568.00  | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc               | UnitedHealth Group Inc                   | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |    585776 | NS      | $310566720.00 | 6.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Vaxcyte Inc                          | Vaxcyte Inc                              | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |   1081918 | NS      | $51877968.00  | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Ventyx Biosciences Inc               | Ventyx Biosciences Inc                   | CUSIP: 92332V107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    533449 | NS      | $17491793.00  | 0.37%             |  |  |  | No            |                  1 | On Loan: —       |
| Vertex Pharmaceuticals Inc           | Vertex Pharmaceuticals Inc               | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |    341726 | NS      | $98683634.00  | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                     | Novo Nordisk A/S                         | CUSIP: K72807132<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    634763 | NS      | $85961729.00  | 1.82%             |  |  |  | No            |                  2 | On Loan: No      |
| Canbridge Pharmaceuticals Inc        | Canbridge Pharmaceuticals Inc USD0.00001 | CUSIP: G1821D109<br>LEI: 8755009KKZM9ETBOF853 | Long             | EC               | CORP              | HK        |   3901000 | NS      | $1224529.00   | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                         | Biohaven Ltd                             | CUSIP: G1110E107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1022578 | NS      | $14193383.00  | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Horizon Therapeutics Plc             | Horizon Therapeutics Plc                 | CUSIP: G46188101<br>LEI: 529900P0GSQ79OOZEV53 | Long             | EC               | CORP              | US        |    536977 | NS      | $61107983.00  | 1.29%             |  |  |  | No            |                  1 | On Loan: No      |
| ICON PLC                             | ICON PLC                                 | CUSIP: G4705A100<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | US        |     82452 | NS      | $16016301.00  | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Jazz Pharmaceuticals PLC             | Jazz Pharmaceuticals PLC                 | CUSIP: G50871105<br>LEI: 635400GAUMJCLEZRRV50 | Long             | EC               | CORP              | US        |    420006 | NS      | $66911156.00  | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                        | Medtronic PLC                            | CUSIP: G5960L103<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | US        |    448902 | NS      | $34888663.00  | 0.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Prothena Corp PLC                    | Prothena Corp PLC                        | CUSIP: G72800108<br>LEI: 5299009ZXQ8NIIJ8OL30 | Long             | EC               | CORP              | US        |    425921 | NS      | $25661740.00  | 0.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC                   | Royalty Pharma PLC - Class A             | CUSIP: G7709Q104<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | US        |    952283 | NS      | $37634224.00  | 0.80%             |  |  |  | No            |                  1 | On Loan: No      |
| STERIS PLC                           | STERIS PLC                               | CUSIP: G8473T100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    170535 | NS      | $31496109.00  | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Dummy Issuer                         | Curevo Inc                               | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   2031087 | NS      | $5330344.00   | 0.11%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Element Biosciences Inc              | Element Biosciences Inc                  | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    425023 | NS      | $6991628.00   | 0.15%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Shoreline Biosciences Inc            | Shoreline Biosciences Inc                | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    747187 | NS      | $6017769.00   | 0.13%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Attralus Inc                         | Attralus Inc                             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    669935 | NS      | $3483662.00   | 0.07%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Lexeo Therapeutics Inc               | LEXEO Therapeutics Inc - Series A        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   3643715 | NS      | $6268975.00   | 0.13%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Lexeo Therapeutics Inc               | LEXEO Therapeutics Inc - Series B        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    883469 | NS      | $1520000.00   | 0.03%             |  |  |  | Yes           |                  3 | On Loan: No      |
| VALENZABIO INC                       | VALENZABIO INC                           | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    700559 | NS      | $6235276.00   | 0.13%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Sonoma Biotherapeutics Inc           | Sonoma Biotherapeutics Inc               | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1924628 | NS      | $5705560.00   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Arbor Biotechnologies Inc            | Arbor Biotechnologies Inc                | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    156426 | NS      | $2591979.00   | 0.06%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Freenome Holdings Inc                | Freenome Holdings Inc                    | CUSIP: N/A<br>LEI: 254900QDTSQ6S0QOCS43       | Long             | EP               | CORP              | US        |    342803 | NS      | $4000511.00   | 0.09%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Hemoshear Therapeutics LLC           | HemoShear Therapeutics LLC               | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    289280 | NS      | $2109430.00   | 0.04%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Disc Medicine Inc                    | Disc Medicine Inc                        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1084584 | NS      | $2127899.00   | 0.04%             |  |  |  | Yes           |                  2 | On Loan: No      |
| Neurogene Inc                        | Neurogene Inc - Series B                 | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1486727 | NS      | $3627614.00   | 0.08%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Twinstrand Biosciences Inc           | TwinStrand Biosciences Inc               | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    344314 | NS      | $749606.00    | 0.02%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Magnolia Medical Technologies        | Magnolia Medical Technologies Inc        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1821717 | NS      | $3092693.00   | 0.07%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Synthekine Inc                       | Synthekine Inc                           | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   2192937 | NS      | $5661001.00   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Asher Biotherapeutics Inc            | Asher Biotherapeutics Inc                | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1214301 | NS      | $1951139.00   | 0.04%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Freenome Holdings Inc                | Freenome Inc                             | CUSIP: N/A<br>LEI: 254900QDTSQ6S0QOCS43       | Long             | EP               | CORP              | US        |    337474 | NS      | $3938322.00   | 0.08%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Neurogene Inc                        | Neurogene Inc                            | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1336317 | NS      | $3260613.00   | 0.07%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Flame Biosciences Inc                | Flame Biosciences                        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    919200 | NS      | $2837662.00   | 0.06%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Bigfoot Biomedical Inc               | Bigfoot Biomedical Inc - Series C-1      | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    168418 | NS      | $1372354.00   | 0.03%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Bigfoot Biomedical Inc               | Bigfoot Biomedical Inc - Series B        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1035873 | NS      | $8440811.00   | 0.18%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Argenx SE                            | Argenx SE (ADR)                          | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             |  | CORP              | US        |    204129 | NS      | $77330189.00  | 1.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                  | Ascendis Pharma A/S (ADR)                | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             |  | CORP              | US        |    456948 | NS      | $55807059.00  | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Bicycle Therapeutics PLC             | Bicycle Therapeutics Ltd (ADR)           | CUSIP: 088786108<br>LEI: 213800XKUI6R7GKC3E43 | Long             |  | CORP              | US        |    528203 | NS      | $15634809.00  | 0.33%             |  |  |  | No            |                  1 | On Loan: —       |
| Centessa Pharmaceuticals PLC         | Centessa Pharmacuticals PLC (ADR)        | CUSIP: 152309100<br>LEI: 213800GIDAARDSKOI827 | Long             |  | CORP              | US        |    691173 | NS      | $2142636.00   | 0.04%             |  |  |  | No            |                  1 | On Loan: —       |
| Clementia Pharmaceuticals Inc        | Clementia Pharmaceuticals Inc CVR        | CUSIP: N/A<br>LEI: N/A                        | Long             |  | CORP              | US        |    874311 | NS      | $1.00         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Legend Biotech Corp                  | Legend Biotech Corp (ADR)                | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             |  | CORP              | US        |    520392 | NS      | $25977969.00  | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                          | Novartis AG (ADR)                        | CUSIP: 66987V109<br>LEI: 5493007HIVTX6SY6XD66 | Long             |  | CORP              | US        |   1405032 | NS      | $127464503.00 | 2.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Zai Lab Ltd                          | Zai Lab Ltd (ADR)                        | CUSIP: 98887Q104<br>LEI: 549300P2UYQ9U5LY1T58 | Long             |  | CORP              | US        |    659746 | NS      | $20254202.00  | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-02-14

**Name of Applicant:** JANUS INVESTMENT FUND

**Signature:** JESPER NERGAARD

**Name of Signer:** JESPER NERGAARD

**Title:** VP, CFO, TREASURER, AND PRINCIPAL ACCOUNTING OFFICER